Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications

Graphical Abstract

Highlights

- Distinct interactomes for TFIIH- versus P-TEFb-phosphorylated mammalian pol II CTD
- CDK7 activity affects CE recruitment, pol II pausing, and pol II termination genome-wide
- CDK7 activity regulates H3K4me3 and H3K36me3 downstream of TSS
- TFIIH- versus P-TEFb-dependent CTD code implicated in multiple co-transcriptional processes

Authors

Christopher C. Ebmeier, Benjamin Erickson, Benjamin L. Allen, ..., William M. Old, David L. Bentley, Dylan J. Taatjes

Correspondence
david.bentley@ucdenver.edu (D.L.B.), taatjes@colorado.edu (D.J.T.)

In Brief

Ebmeier et al. use targeted proteomics to identify distinct interactomes for full-length mammalian pol II CTD phosphorylated by TFIIH or P-TEFb. In vitro and cell-based assays uncover expanded roles for the TFIIH-associated kinase CDK7, including regulation of SETD1A/B methyltransferase activity and regulation of transcription-associated histone modifications (i.e., H3K4me3 and H3K36me3).

Accession Numbers

GSE100040
PXD006485
Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications

Christopher C. Ebmeier,1,2,7 Benjamin Erickson,3,7 Benjamin L. Allen,1 Mary A. Allen,4,6 Hyunmin Kim,3 Nova Fong,3 Jeremy R. Jacobsen,2 Kaiwei Liang,3 Ali Shilatifard,5 Robin D. Dowell,2,4,6 William M. Old,2,6 David L. Bentley,3,* and Dylan J. Taatjes1,6,*

1Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80303, USA
2Department of Molecular, Cell, and Developmental Biology, University of Colorado, Boulder, CO 80309, USA
3Department Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO 80045, USA
4BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA
5Department of Biochemistry & Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
6Linda Cninc Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, CO 80045, USA
7These authors contributed equally
8Lead Contact
*Correspondence: david.bentley@ucdenver.edu (D.L.B.), taatjes@colorado.edu (D.J.T.)

http://dx.doi.org/10.1016/j.celrep.2017.07.021

SUMMARY

CDK7 phosphorylates the RNA polymerase II (pol II) C-terminal domain CTD and activates the P-TEFb-associated kinase CDK9, but its regulatory roles remain obscure. Here, using human CDK7 analog-sensitive (CDK7as) cells, we observed reduced capping enzyme recruitment, increased pol II promoter-proximal pausing, and defective termination at gene 3' ends upon CDK7 inhibition. We also noted that CDK7 regulates chromatid modifications downstream of transcription start sites. H3K4me3 spreading was restricted at gene 5' ends and H3K36me3 was displaced toward gene 3' ends in CDK7as cells. Mass spectrometry identified factors that bound TFIIH-phosphorylated versus P-TEFb-phosphorylated CTD (versus unmodified); capping enzymes and H3K4 methyltransferase complexes, SETD1A/B, selectively bound phosphorylated CTD, and the H3K36 methyltransferase SETD2 specifically bound P-TEFb-phosphorylated CTD. Moreover, TFIIH-phosphorylated CTD stimulated SETD1A/B activity toward nucleosomes, revealing a mechanistic basis for CDK7 regulation of H3K4me3 spreading. Collectively, these results implicate a CDK7-dependent “CTD code” that regulates chromatin marks in addition to RNA processing and pol II pausing.

INTRODUCTION

CDK7 is a subunit within the general transcription factor TFIIH. TFIIH is an integral component of the RNA polymerase II (pol II) pre-initiation complex, but the regulatory functions of CDK7 remain poorly defined, especially in metazoans. During transcription initiation, CDK7 phosphorylates the C-terminal domain (CTD) of the pol II subunit RPB1. Whereas TFIIH appears to be required for pol II transcription genome-wide (Chen et al., 2015a), CDK7 kinase activity is not strictly required for transcription in vivo or in vitro (Kanin et al., 2007; Serizawa et al., 1993). The highly conserved mammalian pol II CTD comprises heptad repeats with a general consensus sequence YSPTSPS. The pol II CTD is dynamically phosphorylated in synchrony with the cycle of transcription initiation, elongation, and termination (Buratowski, 2009; Harlen and Churchman, 2017; Heidemann et al., 2013). CDK7 phosphorylates the CTD on Ser5 and Ser7 (Akhtar et al., 2009; Glover-Cutter et al., 2009; Roy et al., 1994), and phosphorylation at these sites is enriched at the 5’ ends of genes (Harlen and Churchman, 2017; Komarnitsky et al., 2000). The importance of elucidating CDK7 function is highlighted by the fact that a CDK7 inhibitor, THZ1, is a promising new therapeutic strategy that specifically inhibits growth of multiple cancer cell types in pre-clinical studies (Kwiatkowski et al., 2014). A caveat with interpreting the cellular and in vivo effects of THZ1 is that while it is most effective at inhibiting CDK7, it also inhibits other kinases (Kwiatkowski et al., 2014).

In metazoans, CDK7 may indirectly control CTD phosphorylation at Ser2 through activation of CDK9, via T-loop phosphorylation (Larochelle et al., 2012). CDK9 functions within P-TEFb (CDK9 and CCNT1) as a Ser2 CTD kinase, but it can also phosphorylate Ser5 and Ser7 in vitro (Czudnochowski et al., 2012). CDK9 is a positive regulator of transcription elongation that antagonizes pol II promoter-proximal pausing (Kwak and Lis, 2013). The ability of CDK7 to regulate CDK9 suggests that CDK7 may help control pol II pausing, but the evidence is limited. Although activation of CDK9 by CDK7 is expected to inhibit pausing (Larochelle et al., 2012), in vitro and chromatin immunoprecipitation (ChIP) assays at individual genes suggested that CDK7 inhibition by THZ1 or other chemical inhibitors may reduce pausing (Kelso et al., 2014; Nilson et al., 2015). To help resolve this conundrum, we report here a genome-wide analysis of how specific inhibition of CDK7 kinase activity affects pol II promoter-proximal pausing.

The role of human CDK7 in pre-mRNA capping is also unclear. In yeast, CTD Ser5 phosphorylation by the CDK7 homolog Kin28 is required for capping enzyme (CE) recruitment and efficient
Spreading is poorly understood, but it has been correlated with elevated transcription and high pol II occupancy at transcription start sites (TTSS) (Chen et al., 2015c). H3K36me3 is deposited in regions through which pol II has elongated, typically in a broad gradient that increases 5′→3′ across transcription units. In yeast, the Set2 H3K36 methyltransferase interacts directly with Ser2-phosphorylated CTD (Kizer et al., 2005), and the Ser2 kinase Ctk1 facilitates K36 methylation (Xiao et al., 2003). In metazoans, the relationship between CTD phosphorylation and co-transcriptional deposition of H3K36me3 has not been investigated extensively, although in vitro formation of a pol II complex with SETD2 correlated with CTD Ser2 phosphorylation (Yoh et al., 2008).

A more complete understanding of human pol II CTD function requires an improved description of its interactome, including physiologically relevant phosphorylated isoforms. Previous studies addressed this challenge by pol II CTD immunoprecipitation-mass spectrometry (IP-MS) from yeast extracts (Harlen et al., 2016) or through analysis of short CTD peptides for affinity chromatography (Carty et al., 2000; Carty and Greenleaf, 2002; Morris et al., 1999). Here, we completed comparative MS analyses of human proteins bound to unmodified versus TFIIH- or P-TEFb-phosphorylated full-length (i.e., 52 heptad repeats) mammalian pol II CTD. We identified factors that specifically bind TFIIH- versus P-TEFb-phosphorylated CTD, in support of the CTD code hypothesis (Buratowski, 2003). A set of phospho-CTD-specific interactions were pursued further in cells using a well-tested chemical genetics strategy to selectively inactivate human CDK7 (Larochelle et al., 2007). Our results reveal expanded roles for CDK7, many of which appear to be metazoan specific, including regulation of epigenetic modifications (here, the term epigenetic refers to post-translational histone modifications). We identify CDK7 as a key regulator of H3K4me3 spreading in human cells, which has been linked to essential RNA processing (Suzuki et al., 2017) and developmental processes in mammals (Dahl et al., 2016; Liu et al., 2016; Zhang et al., 2016). We further describe how selective inhibition of CDK7 kinase activity broadly affects pol II promoter-proximal pausing, termination, and CE recruitment. Among other things, these results have important implications for developmental diseases linked to CDK7 activity (Coin et al., 1999) and for emerging anti-cancer strategies that target CDK7 (Kwiatkowski et al., 2014).

RESULTS

Targeted Proteomics Identifies Factors Bound to Unmodified versus TFIIH-Phosphorylated Pol II CTD

We purified glutathione S-transferase (GST)-tagged, full-length murine pol II CTD (Figure 1A) and incubated it with ATP and purified human TFIIH (Figure 1B) to make the hyper-phosphorylated form (Figure 1C). The murine pol II CTD varies from the human CTD at just a single residue within the 52 heptad repeats (T4A in repeat 38). Using antibodies against Ser2- or Ser5-phosphorylated CTD, the TFIIH-phosphorylated CTD showed evidence for Ser5, but not Ser2, CTD phosphorylation (Figure 1D).

Each immobilized affinity resin (TFIIH-phosphorylated CTD or unmodified CTD) was incubated with HeLa nuclear extract (NE),
washed, and eluted as outlined in Figure 2A. In each experiment, the NE was supplemented with phosphatase inhibitors to prevent loss of CTD phosphorylation during the incubation (Figure S1). Samples were also treated with benzonase to ensure that no pol II CTD-associated factors were bound via any nucleic acid tether. Samples eluted from each binding experiment were digested with trypsin and worked up for subsequent liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis (see Experimental Procedures). As controls, we completed parallel experiments using GST only as well as experiments with the proximal CTD (heptad repeats 1–24, unmodified or TFIIH-phosphorylated, n = 2 biological replicates each) or distal CTD (heptad repeats 25–52, unmodified or TFIIH-phosphorylated, n = 2 biological replicates each); we also completed experiments in which the unmodified CTD or TFIIH-phosphorylated CTD (proximal, distal, or full length) was incubated with a HeLa nuclear pellet fraction, which is presumed to represent chromatin-associated material (Wuarin and Schibler, 1994).

MS analyses identified dozens of proteins that bound to the full-length unmodified CTD or the TFIIH-phosphorylated CTD (Table S1; Figures 2B and 2C). Consistent with previous studies, the Mediator complex bound the unmodified CTD, but not the TFIIH-phosphorylated CTD (Søgaard and Svejstrup, 2007; Näär et al., 2002), and subunits that comprise the CDK8/CDK19 module (e.g., CDK8, CCNC, MED12, and MED13) were not detected in any of the CTD-bound samples, including the unmodified pol II CTD (Figures 2B and 2C; Table S2). Factors such as PIN1 and mRNA CEs were observed only in TFIIH-phosphorylated CTD samples, in agreement with previous results (Ho et al., 1998; Morris et al., 1999; Pillutla et al., 1998). We also observed that the SETD1A/B histone H3K4 methyltransferase complex specifically bound the TFIIH-phosphorylated CTD. Whereas most proteins/protein complexes bound either the unmodified CTD or the phosphorylated CTD (Figures 2B and 2C; Table S1), an exception was the multi-subunit Integrator complex, which appeared to bind the unmodified and TFIIH-phosphorylated CTD equally well. Comparison of the
interactomes of full-length CTD with proximal (heptad repeats 1–24) or distal (repeats 25–52) CTD showed few differences (Table S1; Figure S2); similarly, few differences were noted from the nuclear pellet versus NE results (Table S1; Figure S2).

CDK7 Inhibition Reduces CTD Ser5 Phosphorylation and CE Recruitment

To follow up on the MS data, we took advantage of a well-characterized human cell line with homozygous mutations in the CDK7 ATP binding site (Larochelle et al., 2007). The CDK7 “analog sensitive” (hereafter called CDK7as) mutant retains CDK7 kinase activity in cells and in vitro; kinase activity is only inhibited upon addition of an ATP analog competitive inhibitor, such as NM-PP1 (Larochelle et al., 2006, 2007). Moreover, because NM-PP1 is too bulky to bind wild-type (WT) CDK7, it has negligible effects on CDK7 activity in WT cells (Larochelle et al., 2007). Western blotting of extracts from WT and CDK7as HCT116 cells, each treated with the inhibitor NM-PP1, confirmed that whereas total pol II remained unchanged (Figure S3), global levels of Ser-5 phosphorylated CTD decreased ~50% in CDK7as cells (Figure 3A), in agreement with previous results (Larochelle et al., 2007). To monitor genome-wide Ser5 phosphorylation of pol II, we performed ChIP sequencing (ChIP-seq) in WT and CDK7as cells, each treated with NM-PP1. These experiments showed that CDK7 inhibition diminished CTD-Ser5-P near the TSS at thousands of genes relative to the WT control (Figure 3B). This reduction corresponded to reduced CTD phosphorylation after normalizing to total pol II ChIP signal (Figure 3C).

Because the MS experiments identified CE subunits (RNGTT and CMTR1) specifically in the TFIIH-phosphorylated samples (Figure 2B; Table S2B), we next assessed whether CDK7 kinase activity affected CE recruitment. We performed CE ChIP-seq (anti-RNGTT) in WT and CDK7as cells, each treated with NM-PP1. In agreement with our previous study of selected genes (Glover-Cutter et al., 2008), ChIP-seq revealed that CE was recruited to gene 5′ ends and associated throughout the gene body and downstream of poly(A) sites (Figure 3D). CDK7 inhibition reduced CE occupancy at the 5′ ends of thousands of transcribed genes (Figure 3E). To determine whether this reduction was an indirect effect of diminished pol II levels, we normalized CE ChIP signals to total pol II. The results confirmed the specific reduction of CE recruitment when CDK7 was inhibited (Figure 3F). Together, the data shown in Figure 3 indicate that the human CDK7 kinase functions to enhance CE recruitment to gene 5′ ends and that this function is likely mediated by Ser5 phosphorylation.
CTD phosphorylation as suggested by in vitro binding studies (Ho and Shuman, 1999).

CDK7 Kinase Activity Regulates H3K4 Trimethylation at Gene 5’ Ends

The proteomics data showed that all subunits of the H3K4 methyltransferases SETD1A/B bound the TFIIH-phosphorylated CTD, but not the unmodified CTD (Figures 2B and 2C; Table S2). To investigate the functional significance of SETD1A/B interaction with TFIIH-phosphorylated CTD, we examined how CDK7 inhibition affected H3K4 trimethylation, genome-wide, using ChiP-seq in WT and CDK7as cells, each treated with NM-PP1. These experiments revealed that CDK7 inhibition reduced the level of H3K4me3 at over 1,200 genes (Table S3) and reduced spreading of H3K4me3 into gene bodies (Figures 4A–4D; replicates in Figure S4B–S4E), while global levels of H3K4me3 and SETD1A largely remained constant (Figure S3). Reduced H3K4me3 at these genes was not due to indirect effects from reduced total histone H3 occupancy (Figure 4E) or reduced pol II occupancy, as shown by anti-pol II ChiP-seq (Figure S6E). Interestingly, CDK7 inactivation appeared to reduce H3K4 trimethylation at nucleosomes downstream of the TSS far more than upstream.
Figure 5. CDK7 Inhibition Increases Pol II Pause Index and Alters Pol II Occupancy at Gene 3’ Ends

(A–C) UCSC genome browser screenshots (ACTG1, A; RPS19, B; ERRF11, C) of anti-pol II ChIP-seq signals (normalized to yeast spike-in) in WT and CDK7as cells, each treated with NM-PP1.

(D) Metaplots of mean anti-pol II ChIP-seq signals (normalized to total number of mapped reads) in WT and CDK7as cells (as in A–C), each treated with NM-PP1 inhibitor for well-expressed genes.

(E) CDK7 inhibition increases pol II pausing index. Cumulative index plots of pausing index (log2 pol II promoter density/pol II gene body density; promoter defined as −30 to +300 bases relative to TSS and gene body as +301 to poly(A) site), calculated from anti-pol II ChIP signals in WT and CDK7as cells, each treated with NM-PP1. Rightward shift curve in CDK7as cells noted by red arrow. p values were calculated using a two-sided Kolmogorov-Smirnov test.

(legend continued on next page)
(Figure 4A). These experiments show that human CDK7 functions to modulate H3K4 trimethylation at gene 5’ ends and that CDK7 activity regulates H3K4me3 spreading into gene bodies.

**TFIIH-Phosphorylated CTD Activates SETD1A/B Methyltransferase Activity In Vitro**

Previous reports have shown that the phosphorylated pol II CTD can stimulate CE activity (Ho and Shuman, 1999), thereby ensuring that CE is most active when associated with pol II. Similarly, we wondered whether TFIIH-phosphorylated pol II CTD might stimulate SETD1A/B histone methyltransferase activity. To test this idea, we completed enzymatic assays with purified nucleosomal templates, the SETD1A or SETD1B complex, +pol II CTD in its unmodified or TFIIH-phosphorylated forms. As shown in Figure 4F (see also Figure S5), the activity of both the SETD1A and SETD1B complex was stimulated by the TFIIH-phosphorylated CTD (but not unmodified CTD), suggesting that upon binding the phosphorylated pol II CTD, the SETD1A/B H3K4 methyltransferases are allosterically activated. Notably, the activation affected only H3K4me3, suggesting the TFIIH-phosphorylated CTD specifically activates H3K4 trimethylation from mono- or di-methylated intermediates (Figure S5).

**CDK7 Inhibition Increases Pol II Pausing Index and Delays Termination**

Human CDK7 activity has been implicated in both positive and negative control of early pol II elongation on several genes in cells and in vitro (Glover-Cutter et al., 2009; Kelso et al., 2014; Larochelle et al., 2012; Nilson et al., 2015), but its effects have yet to be examined genome-wide. We carried out ChIP-seq experiments to determine how pol II occupancy was affected by CDK7 inhibition. Biological replicate experiments show that CDK7 inhibition caused a widespread increase in pol II occupancy at the TSS relative to gene bodies. This is evident from inspection of individual genes (Figures 5A–5C; replicates in Figure S6A–S6C) and in metaplots of thousands of genes (Figure 5D). These results demonstrated that a major genomewide effect of CDK7 inhibition is increased pol II pausing index (the ratio of pol II density at the promoter/gene body), as shown in Figure 5E (replicate in Figure S6D). Consistent with enhanced pol II pausing upon CDK7 inhibition, anti-histone H3 ChIP-seq demonstrated greater displacement of nucleosomes from the TSS (Figures 4E and S4A) (Gilchrist et al., 2008). Although CDK7 inhibition did not reduce pol II occupancy at most promoters, we found that it markedly diminished recruitment to super-enhancers in CDK7as cells (Figure S6F). This supports the concept that expression of genes driven by super-enhancers is highly dependent on CDK7 (Kwiatkowski et al., 2014).

As an additional control, we investigated whether THZ1, a covalent kinase inhibitor with specificity for CDK7 (Kwiatkowski et al., 2014), similarly affected pol II pausing. HCT116 cells were treated with THZ1 (1 μM) or DMSO for 1 hr and subjected to anti-pol II ChIP-seq. This showed that the pol II pausing index increased even with this short THZ1 treatment, although the effect was more modest than in CDK7as cells (Figure 5F). Moreover, a redistribution of pol II toward 5’ ends was detected on individual genes upon THZ1 treatment (Figures 5G and S6G–S6I). The response to THZ1 therefore independently supported the conclusion that CDK7 inhibition generally increases pol II pausing.

The pol II ChIP-seq data in NM-PP1-treated WT versus CDK7as cells also revealed that pol II occupancy extended further downstream of the 3’ poly(A) site in CDK7as cells, consistent with delayed transcription termination. This was evident on individual genes (Figures 5A–5C, red arrows) and in metagene plots representing thousands of genes (Figure 5H). In sum, these data reveal that human CDK7 kinase activity regulates promoter-proximal pol II pausing and impacts late stages of pol II transcription by delaying termination at gene 3’ ends.

**Effects of CDK7 Inhibition on mRNA Levels**

We conducted RNA-seq analyses of WT and CDK7as cells, each treated with NM-PP1, to determine how global mRNA levels were affected by CDK7 inhibition (Table S4). After 24 hr NM-PP1 treatment, we observed 1,430 upregulated and 3,755 downregulated genes in CDK7as cells (p < 0.01; Figure S7A). In agreement with impaired termination downstream of genes (Figure 5H), slightly more reads mapped outside the coding region in CDK7as cells, as shown in Figure S7B. As expected, many, but not all, genes with lower (1.5×) pol II gene body ChIP-seq signal in CDK7as cells (Table S5) showed reduced mRNA levels (Figure S7C; p < 2.22E-16). We also observed a significant (p < 2.22E-16) overlap between downregulated genes and those with reduced H3K4 trimethylation at the promoter (Figure S7D). A correlation between mRNA downregulation and reduced CE recruitment was not observed, which may reflect compensatory mechanisms involving mRNA stability, as reported in yeast upon Kin28 inactivation (Rodriguez-Molina et al., 2016).

**The H3K36 Methyltransferase SETD2 Specifically Binds P-TEFb-Phosphorylated Pol II CTD**

CDK9, as part of P-TEFb, phosphorylates the pol II CTD with a specificity distinct from CDK7. To compare and contrast CDK7 versus CDK9 in the recruitment of factors to the phosphorylated pol II CTD, we completed a series of biochemical and proteomics experiments with the P-TEFb phosphorylated pol II CTD. As with TFIIH, P-TEFb (Figure 6A) efficiently phosphorylated the full-length pol II CTD in vitro to generate a single super-shifted, hyper-phosphorylated CTD (Figure 6B). Unlike the TFIIH-modified CTD, western blot experiments showed both Ser2- and Ser5-phosphorylation with P-TEFb, consistent with previous observations (Figure 6C) (Czudnochowski et al., 2012).

See also Figures S3, S4, S6, and S7.
Using the same protocol described for the TFIIH-phosphorylated pol II CTD (Figure 6D), we isolated factors bound to the P-TEFb-modified pol II CTD (Figures S1E and S1F) and identified them with LC-MS/MS. The data are summarized in Table S1 (n = 3 biological replicates), which include experiments with the proximal (repeats 1–24) and distal (repeats 25–52) portions of the pol II CTD (n = 2 biological replicates each; Table S1; Figure S2) and the nuclear pellet material (Table S1; Figure S2). Although distinct proteins bound P-TEFb versus TFIIH-phosphorylated CTD (Table S6), many factors were shared. For example, PCIF, PIN1, and subunits of the SETD1A/B, PAF1, Integrator, and CE each appeared to bind the TFIIH-modified or P-TEFb-modified CTD equally well (Figure 6E). One clear exception was the SETD2 protein, which was not detected in any TFIIH-phosphorylated CTD binding experiment but was abundant in the P-TEFb-phosphorylated CTD sample (Figure 6E; Table S6).

**CDK7 Inhibition Reduces CTD Ser2 Phosphorylation and Displaces H3K36me3 toward Gene 3’ Ends**

CDK7 activates the P-TEFb kinase (CDK9) via T-loop phosphorylation (Larochelle et al., 2012); therefore, SETD2 binding to the
CTD in a P-TEFb-dependent manner suggested that H3K36 methylation could potentially be modulated by CDK7 kinase activity. We probed pol II CTD Ser2 phosphorylation and found that global levels of Ser2 CTD phosphorylation decreased ~30%–40% in CDK7as cells compared to WT controls (Figure 7A) consistent with previous results (Laroche et al., 2012). Anti-phospho-Ser2 CTD ChIP-seq in WT and CDK7as cells, each treated with the inhibitor NM-PP1, revealed a widespread reduction in the Ser2-P CTD ChIP signal at the 3′ end of genes relative to the 5′ end (Figure 7B) in CDK7as cells. These data also revealed an extension of the Ser2-P signal into 3′ flanking regions (Figure 7C) in CDK7as cells, consistent with delayed termination as shown in Figures 5A–5C and 5H.

The data in Figures 7A–7C further support the findings of Fisher et al. that human CDK7 activates CDK9 (Laroche et al., 2012). Given that SETD2 associated specifically with the P-TEFb-phosphorylated pol II CTD (Figure 6E), we next asked whether CDK7 affected H3K36 trimethylation in cells. Quantitative western blots showed no global change in H3K36me3 levels when CDK7 was inhibited (Figure S3); however, anti-H3K36me3 ChIP-seq revealed a general re-positioning toward 3′ ends of transcribed genes (Figures 7D–7F). Furthermore, we observed that the H3K36me3 mark extended further into 3′ flanking regions, as shown in the metaplots (Figure 7D) and from inspection of individual genes (Figures 7E and 7F; replicates in Figures S4F and S4G). This widespread H3K36me3 relocalization was not due to changes in histone H3 occupancy, as shown by anti-H3 ChIP-seq experiments (Figure S4A), suggesting that human CDK7 activity regulates the deposition of this transcription-coupled chromatin mark.

**DISCUSSION**

The “CTD code” hypothesis suggests that distinct patterns of post-translational modifications direct the binding of specific factors during different stages of pol II transcription (Buratowski, 2003). By combining cell-based assays (e.g., ChIP-seq) with biochemical and MS experiments, we were able to link CDK7-kinase-dependent changes in cells to biochemically validated interactions with the pol II CTD. This study advances the field by probing the mammalian pol II CTD interactome using native, full-length, 52-heptad-repeat phosphorylated CTD substrates and distinguishing TFIIH- and P-TEFb-specific effects. The data provide evidence for a CTD code while indicating that it is...
not entirely kinase specific. These results are in general accord with recent findings that suggest the phospho-specific CTD code is of restricted complexity (Harlen et al., 2016; Schüller et al., 2016; Suh et al., 2016).

CDK7 is linked to developmental disorders and is a promising target for anti-cancer therapeutics; thus, it is important to understand how CDK7 kinase activity regulates human gene expression. Experiments with the yeast CDK7 homolog, Kin28, have contributed greatly to our understanding of human CDK7 (Hong et al., 2009; Kanin et al., 2007; Komarnitsky et al., 2000; Schroeder et al., 2000; Schwer and Shuman, 2011; Suh et al., 2016); however, transcription regulatory mechanisms are distinct between yeast and humans (Levine et al., 2014). For example, studies with Kin28 cannot address promoter-proximal pausing or CDK7-dependent activation of CDK9, which appear to be metazoan specific (Larocheille et al., 2012; Mayer et al., 2010). Whereas some of our findings showed conserved functions for human CDK7 (e.g., TFIIH-phosphorylated CTD recruits CE), others were completely the opposite of what could be predicted based upon yeast data (e.g., CDK7-dependent regulation of H3K4me3 spreading) or go beyond what has been done in yeast or other model organisms (e.g., delineation of TFIIH- versus P-TEFb-phosphorylated CTD interactome or allosteric activation of SETD1A/B by TFIIH-phosphorylated CTD). Some of the key findings and implications of this study are described further below.

### CDK7, Promoter-Proximal Pol II Pausing and Termination at Gene 3’ Ends

Our results have revealed functions for human CDK7 in pol II transcription that are mediated, at least in part, by differential factor association with the phosphorylated pol II CTD. We observed a genome-wide increase in the pol II pausing index when CDK7 was inhibited, either by NM-PP1 in CDK7-as cells or THZ1 in WT cells (Figure 5). These results are consistent with CDK7-mediated activation of the pause release factor, P-TEFb, by CDK9 T-loop phosphorylation (Larocheille et al., 2012). Interestingly, P-TEFb was observed to interact with the CTD in both its TFIIH-phosphorylated and unphosphorylated forms (Figures 2B and 2C). Whereas this would not impact the CTD phosphorylation state in our MS or biochemical experiments (e.g., ATP is absent in NEs), it suggests P-TEFb could associate with pol II at early stages of transcription, including pre-initiation complex assembly. This is consistent with results that suggest promoter-associated P-TEFb remains in a latent state that requires subsequent activation (Larocheille et al., 2012; McNamara et al., 2016). Reduced PAF1 complex association with the pol II CTD in CDK7-inhibited cells might also contribute to the increased pol II pause index. The PAF1 complex regulates pol II promoter-proximal pausing (Chen et al., 2015b; Yu et al., 2015), and subunits of this complex (CDC73, CTR9, PAF1) were enriched in the TFIIH-phosphorylated CTD samples (Figure 2C).

In addition to altered pol II pausing, we observed elevated pol II occupancy beyond poly(A) sites in gene 3’ flanking regions, consistent with delayed termination (Figure 5H). How human CDK7 activity might promote termination is unclear, but it could potentially stimulate cleavage/polyadenylation or slow pol II elongation to facilitate termination by the torpedo mechanism (Fong et al., 2015). CDK7 effects on termination may also be mediated via recruitment of SETD1A/B or PAF1 complexes (Figure 2O), both of which have been linked to regulation of pol II termination (Austenaa et al., 2015; Yang et al., 2016). In contrast to CDK7 inhibition in human cells, Kin28 inhibition in yeast showed depleted pol II occupancy at gene 3’ ends, likely due to premature termination (Kim et al., 2010; Rodríguez-Molina et al., 2016). These results suggest distinct regulatory roles for human CDK7 and yeast Kin28 at gene 3’ ends, although the precise molecular mechanisms remain to be determined.

### Human CDK7 Governs CE Recruitment

Our targeted proteomics data revealed that the guanylyltransferase/phosphatase (RNGTT) and the 2’-hydroxyl methyltransferase (CMTR1) CEs bound the phosphorylated pol II CTD, suggesting that synthesis of cap0 and cap1 structures could be coupled through the human pol II CTD. ChIP-seq experiments (anti-RNGTT) revealed a decrease in CE and pol II CTD Ser5 phosphorylation at gene 5’ ends upon CDK7 inhibition (Figure 3), in agreement with results in yeast (Ho and Shuman, 1999; Komarnitsky et al., 2000; Schroeder et al., 2000; Schwer and Shuman, 2011; Viladevall et al., 2009). Our findings with human CDK7 suggest a conserved mechanism whereby pol II CTD Ser5 phosphorylation promotes CE recruitment but leaves open the possibility that CDK7 may also antagonize a CE-inhibitory factor (Nilson et al., 2015). Combined with ChIP-seq data that link CDK7 kinase activity to pol II pausing (Figure 5), it appears that human CDK7 may control a proposed checkpoint that coordinates co-transcriptional capping with the pol II transition to productive elongation (Mandal et al., 2004; Pei and Shuman, 2002).

### CDK7 Regulates H3K4me3 Spreading at Gene 5’ Ends

CDK7 inhibition markedly reduced spreading of H3K4me3 into gene bodies (Figure 4). We also observed that the CDK7 effect on H3K4me3 spreading was asymmetric; that is, CDK7 inhibition reduced H3K4me3 spreading downstream of the TSS more than upstream (Figure 4). Others have noted similar H3K4me3 asymmetry at bidirectional promoters, with increased H3K4me3 (versus H3K4me2) in the downstream, or sense, direction (Duttke et al., 2015). Interestingly, we observed that the TFIIH-phosphorylated CTD activated SETD1A/B and specifically elevated H3K4me3 levels (versus H3K4me2) on nucleosomal templates in vitro (Figure 5S). Taken together, these findings suggest a mechanism whereby CDK7 may help preferentially establish H3K4me3 marks downstream of bidirectional promoters.

Reduced H3K4me3 spreading upon CDK7 inhibition may involve a combination of CDK7-dependent functions. Because a comprehensive understanding of CDK7 substrates is lacking, we cannot exclude other potential kinase targets. However, our proteomics data and in vitro enzymatic assays provide a mechanistic basis for how CDK7 kinase activity may regulate H3K4me3 spreading that involves both the recruitment and subsequent activation of human SETD1A/B complexes. Results in yeast have linked Set1 binding to Ser5-phosphorylated CTD and Kin28 activity (Ng et al., 2003) and thus support our
conclusion that human CDK7 regulates H3K4me3. However, H3K4me3 spreading appears to be regulated by completely different mechanisms in yeast. H3K4 methylation is regulated by the yeast pol II CTD Ser2 kinase Ctk1 (Wood et al., 2007; Xiao et al., 2003), whose human ortholog is CDK12/13. Upon deletion of yeast Ctk1, H3K4me3 spreading was shown to increase (Xiao et al., 2007). Thus, a different kinase, CDK7, regulates H3K4me3 spreading in human cells, and kinase inhibition has opposing effects compared with yeast (i.e., deletion of Ctk1 increased spreading in yeast, whereas inhibition of CDK7 decreased H3K4me3 spreading in human cells).

Previous studies have shown that H3K4me3 spreading correlates with elevated transcription and high pol II occupancy at the TSS (Chen et al., 2015c). Moreover, H3K4me3 spreading is dynamic and correlates with transcriptional activation of key developmental genes in mouse embryos (Dahl et al., 2016; Liu et al., 2016; Zhang et al., 2016) and with sites of active microRNA processing in human cells (Suzuki et al., 2017). Our results now link CDK7 kinase activity to these biological processes, although further study is needed to precisely define potential CDK7-dependent regulatory roles.

**CDK7, P-TEFb, and H3K36me3**

The proteomics data revealed that SETD2, which is responsible for global deposition of H3K36me3 (Edmunds et al., 2008), associated with the pol II CTD phosphorylated by P-TEFb, but not TFIIH. SETD2 therefore appears to recognize a P-TEFb-specific CTD phosphorylation pattern. Although SETD2 occupancy cannot be tested directly because reliable ChIP antibodies remain unavailable, we observed a global shift in H3K36me3 distribution toward 3’ ends of transcribed genes upon CDK7 inhibition (Figures 7D–7F). Because CDK7 is known to activate P-TEFb via CDK9 T-loop phosphorylation (a mechanism that appears to be metazoan-specific) (Larocheille et al., 2012), we hypothesize that CDK7-dependent changes in H3K36me3 result from reduced CDK9 activity. Consistent with this hypothesis, we observed reduced levels of phospho-Ser2 CTD in CDK7as cells compared with controls using quantitative western blotting and ChIP-seq (Figures 7A–7C). In yeast, H3K36me3 is dependent upon a different pol II CTD kinase, Ctk1 (Xiao et al., 2003), whose human ortholog is CDK12/13. CDK7-dependent regulation of H3K36me3 therefore appears to be specific to metazoans, although downstream chromatin modifications have yet to be investigated in Kin28-inhibited yeast cells.

**Concluding Remarks**

By linking human CDK7 activity to changes in H3K4me3 and H3K36me3 throughout the genome, our results suggest an expanded role for this kinase as an upstream regulator of transcription-associated epigenetic modifications. These findings point to additional mechanistic links with co-transcriptional mRNA processing and DNA methylation, which is a heritable epigenetic mark. Both H3K4me3 and H3K36me3 are implicated in splicing (Kolasinska-Zwierz et al., 2009; Simon et al., 2014; Sims et al., 2007; Spies et al., 2009), and it will be interesting in future studies to determine how CDK7 inhibition may affect mRNA processing. H3K4me3 and H3K36me3 levels also correlate with DNA methylation in opposing ways; H3K4me3 is anti-correlated, whereas H3K36me3 directly correlates with DNA methylation (Morselli et al., 2015; Simon et al., 2014). In fact, the DNA methyltransferase DNMT3A associates with H3K36me3 and mutations in SETD2 induce regions of DNA hypo-methylation (Cancer Genome Atlas Research Network, 2013). Our results also have important implications for emerging anti-cancer therapeutic strategies that target CDK7 (Kwiatkowski et al., 2014), as transient or prolonged CDK7 inhibition could result in heritable epigenetic changes. Furthermore, developmental diseases such as xeroderma pigmentosum or trichothiodystrophy display reduced CDK7 kinase activity (Coin et al., 1999), and our results suggest that epigenetic changes may contribute to the pathology of these diseases.

**EXPERIMENTAL PROCEDURES**

Details regarding cell lines, protein purifications, antibodies, and biochemical assays are provided in Supplemental Experimental Procedures.

**Mass Spectrometry and Data Analyses**

Samples were separated on a 0.075 × 250 mm 1.7 μm 130A C18 nanoAcquity UPLC column at 300 nL/min with a nanoAcquity UPLC system (Waters) using mobile phases 0.1%(v/v) formic acid in liquid chromatography mass spectrometry (LCMS) water and 0.1%(v/v) formic acid in acetonitrile. The entire tryptic peptide sample was analyzed with an LTQ-Orbitrap (Thermo Scientific) over a 2-hr gradient. All raw files were processed using MaxQuant version 1.5.2.8 (Cox and Mann, 2008) searching at 1% false discovery rate (FDR) at the peptide and protein levels against the UniProt human database (version 20150401). MaxQuant intensities were inputted into the algorithm Significance Analysis of INTeractome (SAINT) (Choi et al., 2012), and interactors with a SAINT score ≥0.5 were inputted into the STRING database data visualization package (Szklarczyk et al., 2015) to create the STRING diagrams.

**ChIP-Seq**

ChIP from human extracts was completed as described previously (Kim et al., 2011; Schroeder et al., 2009). Enzymatic steps and size fractionation of libraries were done on AMPPure XP SPRI beads (Beckman Coulter Genomics) and sequenced on the Illumina Hi-Seq platform. Reads were mapped to the hg19 UCSC human genome (February 2009) with Bowtie version 0.12.5 (Langmead et al., 2009) (Table S7). We generated bed and wig profiles using 50 bp bins and 200 bp windows assuming a 180 bp fragment size shifting effect. Results were viewed with the UCSC genome browser, and meta-plots were generated using R. For meta-plots of gene bodies, the region between +500 relative to the TSS and −500 relative to the poly(A) site was divided into 20 variable-length bins. Metaplots of human genes were from a list of 5,507 well-expressed genes separated from their neighbors by >2 kb (Brannan et al., 2012). Metaplots include all genes in common between the datasets for which a minimum ChIP signal was obtained. Unless noted otherwise, mean read counts per bin were plotted in the metaplots.

**RNA-Seq Library Preparation**

Ribosomal RNA was removed using the New England Biolabs (NEB) ribosome removal kit, and libraries were prepared using the NEB ultra directional kit, with RNA fragmentation for 8 min and 15 PCR cycles. RNA sequencing (RNA-seq) libraries of 1 × 151 nucleotides were sequenced on an Illumina Hi-Seq with an average of 60 million reads per sample.

**RNA-Seq**

RNA-seq reads from three biological replicates of WT CDK7 and CDK7as HCT116 cells treated with 3NM-PP1 (10 μM, 24 hr) were mapped using HISAT2 (Pertea et al., 2016) to the Ensembl Grcbh human transcriptome (Table S7). Read coverage (number of overlapping reads per base pair) was calculated over non-overlapping exons. The exon counts were aggregated for each gene to build a gene-counting table. Using edger (Robinson et al., 2009), multiple sets of differentially expressed genes were identified.
2010), we tested for significant differences in mRNA expression between CDK7 and CDK7as cells. Generalized liner model (GLM)-based tag-wise dispersions were estimated with a default option and used in the likelihood ratio test. The significance threshold p = 0.001 was used. The significance of overlaps between regulated RNAs and those genes with altered pol II and H3K4me3 density was calculated using a hypergeometric test with the hyperf test in R with an assumption of 40,000 total genes.

REFERENCES


